AU2001285067A1 - Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases - Google Patents
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseasesInfo
- Publication number
- AU2001285067A1 AU2001285067A1 AU2001285067A AU8506701A AU2001285067A1 AU 2001285067 A1 AU2001285067 A1 AU 2001285067A1 AU 2001285067 A AU2001285067 A AU 2001285067A AU 8506701 A AU8506701 A AU 8506701A AU 2001285067 A1 AU2001285067 A1 AU 2001285067A1
- Authority
- AU
- Australia
- Prior art keywords
- treating
- disease
- neurodegenerative diseases
- treatment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
- C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23378600P | 2000-09-19 | 2000-09-19 | |
US60/233,786 | 2000-09-19 | ||
PCT/US2001/025892 WO2002024672A2 (en) | 2000-09-19 | 2001-08-17 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001285067A1 true AU2001285067A1 (en) | 2002-04-02 |
Family
ID=22878678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001285067A Abandoned AU2001285067A1 (en) | 2000-09-19 | 2001-08-17 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050004167A1 (en) |
EP (1) | EP1320523B1 (en) |
JP (1) | JP2004509880A (en) |
AT (1) | ATE298323T1 (en) |
AU (1) | AU2001285067A1 (en) |
BR (1) | BR0113974A (en) |
CA (1) | CA2416136A1 (en) |
DE (1) | DE60111639T2 (en) |
DO (1) | DOP2001000250A (en) |
ES (1) | ES2241861T3 (en) |
GT (1) | GT200100188A (en) |
MX (1) | MXPA03001277A (en) |
PA (1) | PA8528901A1 (en) |
PE (1) | PE20020362A1 (en) |
TN (1) | TNSN01135A1 (en) |
UY (1) | UY26939A1 (en) |
WO (1) | WO2002024672A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02010231A (en) * | 2001-11-27 | 2004-12-13 | Warner Lambert Co | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases. |
MXPA02010430A (en) * | 2001-11-27 | 2003-06-02 | Warner Lambert Co | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases. |
FR2862646B1 (en) * | 2003-11-20 | 2006-02-24 | Merck Sante Sas | NOVEL ANTIDIABETIC COMPOUNDS CONTAINING BENZOFURAN, BENZOTHIOPHENIC DERIVATIVES |
US20080188472A1 (en) * | 2004-03-08 | 2008-08-07 | Prosidion Limited | Indole-2-Carboxylic Acid Hydrazides |
EP2717869B1 (en) * | 2011-06-13 | 2019-02-27 | Ergon Pharmaceuticals LLC | Methods of treatment using a bcat1 inhibitor |
US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
WO2017185073A1 (en) | 2016-04-21 | 2017-10-26 | Eip Pharma, Llc | Compositions and methods for treating dementia |
US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3606949A1 (en) * | 1986-03-04 | 1987-09-10 | Basf Ag | Quinoline derivatives and their use for controlling undesired plant growth |
EP0224823A3 (en) * | 1985-11-26 | 1988-02-10 | BASF Aktiengesellschaft | Quinoline derivatives and their use in combating unwanted plant growth |
EP0671654B1 (en) * | 1994-03-11 | 1997-09-10 | Agfa-Gevaert N.V. | Photographic material containing a new type of hydrazide |
-
2001
- 2001-08-17 AT AT01964182T patent/ATE298323T1/en not_active IP Right Cessation
- 2001-08-17 DE DE60111639T patent/DE60111639T2/en not_active Expired - Fee Related
- 2001-08-17 EP EP01964182A patent/EP1320523B1/en not_active Expired - Lifetime
- 2001-08-17 ES ES01964182T patent/ES2241861T3/en not_active Expired - Lifetime
- 2001-08-17 BR BR0113974-6A patent/BR0113974A/en not_active IP Right Cessation
- 2001-08-17 CA CA002416136A patent/CA2416136A1/en not_active Abandoned
- 2001-08-17 MX MXPA03001277A patent/MXPA03001277A/en not_active Application Discontinuation
- 2001-08-17 WO PCT/US2001/025892 patent/WO2002024672A2/en active IP Right Grant
- 2001-08-17 AU AU2001285067A patent/AU2001285067A1/en not_active Abandoned
- 2001-08-17 JP JP2002529082A patent/JP2004509880A/en active Pending
- 2001-09-07 PE PE2001000902A patent/PE20020362A1/en not_active Application Discontinuation
- 2001-09-12 GT GT200100188A patent/GT200100188A/en unknown
- 2001-09-17 UY UY26939A patent/UY26939A1/en not_active Application Discontinuation
- 2001-09-18 TN TNTNSN01135A patent/TNSN01135A1/en unknown
- 2001-09-19 PA PA20018528901A patent/PA8528901A1/en unknown
- 2001-09-20 DO DO2001000250A patent/DOP2001000250A/en unknown
-
2004
- 2004-01-26 US US10/765,002 patent/US20050004167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002024672A3 (en) | 2003-03-06 |
TNSN01135A1 (en) | 2005-11-10 |
CA2416136A1 (en) | 2002-03-28 |
DE60111639T2 (en) | 2006-04-27 |
EP1320523A2 (en) | 2003-06-25 |
US20050004167A1 (en) | 2005-01-06 |
MXPA03001277A (en) | 2004-07-30 |
DE60111639D1 (en) | 2005-07-28 |
ES2241861T3 (en) | 2005-11-01 |
BR0113974A (en) | 2003-07-01 |
DOP2001000250A (en) | 2002-06-15 |
ATE298323T1 (en) | 2005-07-15 |
WO2002024672A2 (en) | 2002-03-28 |
EP1320523B1 (en) | 2005-06-22 |
PE20020362A1 (en) | 2002-05-11 |
UY26939A1 (en) | 2002-04-26 |
JP2004509880A (en) | 2004-04-02 |
GT200100188A (en) | 2002-04-22 |
PA8528901A1 (en) | 2003-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02010231A (en) | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases. | |
WO2001081312A3 (en) | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore | |
IL168365A (en) | Use of a rasagaline with or without riluzole for preparing a medicament for treating amyotrophic lateral sclerosis | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
DE69921340D1 (en) | BRANCHED ALKYLPYRROLIDIN-3-CARBONIC ACIDS | |
MXPA05011150A (en) | (HETERO) ARYLAMIDE 2-HYDROXY-3-DIAMINOALKANES FOR USE IN THE TREATMENT OF ALZHEIMERaCOES DISEASE. | |
EP1562897A4 (en) | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease | |
EP1983000A3 (en) | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity | |
MXPA04000328A (en) | Statine derivatives for the treatment of alzheimer's disease. | |
NZ276892A (en) | Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof | |
AU2001285067A1 (en) | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | |
WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
MXPA04000338A (en) | Diaminediols for the treatment of alzheimer's disease. | |
WO2005097762A3 (en) | 1,3,4-oxadiazol-2-ones as ppar delta modulators | |
ATE359794T1 (en) | 3, 7 THIAPROSTANIC ACID DERIVATIVES AS AN AGENT FOR REDUCING INTERNAL EYE PRESSURE | |
BR9503694A (en) | Composite method for the treatment of a mammal and pharmaceutical composition | |
PL1697394T3 (en) | Comt inhibitors | |
DE60234919D1 (en) | 3, 7 OR 3 AND 7 THIA- OR OXAPROSTANIC ACIDS DERIVATIVES AS A MEANS FOR REDUCING EYE REMINDER | |
MXPA03011521A (en) | Aminediols as agents for the treatment of alzheimer's disease. | |
BR0314081A (en) | Combination therapy comprising a bisphosphonate and an hmg-coa reductase inhibitor | |
BR0316163A (en) | Histone Deacetylase Inhibitors for Treatment of Degenerative Eye Diseases | |
MXPA02010430A (en) | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases. | |
MY126117A (en) | Pharmaceutical compositions |